Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment

The Lancet Respiratory Medicine

Volumn 1, Issue 6, 2013, Pages 462-470

  Friedrich, Sven O ^a   Rachow, Andrea ^b,c,d   Saathoff, Elmar ^c   Singh, Kasha ^e   Mangu, Chacha D ^b   Dawson, Rodney ^g   Phillips, Patrick PJ ^h   Venter, Amour ^a   Bateson, Anna ^e   Boehme, Catharina C ⁱ   Heinrich, Norbert ^c   Hunt, Robert D ^e   Boeree, Martin J ^f   Zumla, Alimuddin ^e   McHugh, Timothy D ^e   Gillespie, Stephen H ^j   Diacon, Andreas H ^a   Hoelscher, Michael ^c,d  

^a UNIVERSITY OF STELLENBOSCH   (South Africa)

^b National Institute of Medical Research Mbeya Medical Research Centre   (Tanzania)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d German Center for Infection Research   (Germany)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^g UNIVERSITY OF CAPE TOWN   (South Africa)

^h MRC CLINICAL TRIALS UNIT   (United Kingdom)

ⁱ Foundation for Innovative and New Diagnostics   (Switzerland)

^j UNIVERSITY OF ST ANDREWS   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL DNA; ETHAMBUTOL; ISONIAZID; MOXIFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; BIOLOGICAL MARKER; TUBERCULOSTATIC AGENT;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM CULTURE; BACTERIUM DETECTION; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE MARKER; DRUG MONITORING; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EARLY DIAGNOSIS; FEMALE; HUMAN; LABORATORY DEVICE; LIQUID CULTURE; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; SPUTUM SMEAR; TREATMENT DURATION; BIOASSAY; CLINICAL TRIAL; GENETICS; ISOLATION AND PURIFICATION; METABOLISM; MICROBIOLOGY; MIDDLE AGED; PROCEDURES; REAL TIME POLYMERASE CHAIN REACTION; RECURRENT DISEASE; SPUTUM; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

ADULT; ANTITUBERCULAR AGENTS; BIOLOGICAL ASSAY; BIOMARKERS; DNA, BACTERIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RECURRENCE; SENSITIVITY AND SPECIFICITY; SPUTUM; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

EID: 84881369293     PISSN: 22132600     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2213-2600(13)70119-X     Document Type: Article

References (34)

1. Raviglione M, Marais B, Floyd K, et al. Scaling up interventions to achieve global tuberculosis control: progress and new developments. Lancet 2012, 379:1902-1913.
2. Zumla A, Hafner R, Lienhardt C, Hoelscher M, Nunn A Advancing the development of tuberculosis therapy. Nat Rev Drug Discov 2012, 11:171-172.
3. Phillips PP, Gillespie SH, Boeree M, et al. Innovative trial designs are practical solutions for improving the treatment of tuberculosis. J Infect Dis 2012, 205(suppl 2):S250-S257.
4. Wallis RS, Perkins MD, Phillips M, et al. Predicting the outcome of therapy for pulmonary tuberculosis. Am J Respir Crit Care Med 2000, 161(4 pt 1):1076-1080.
5. Yeager HLJ, Smith LR, LeMaistre CA Quantitative studies of mycobacterial populations in sputum and saliva. Am Rev Respir Dis 1967, 95:998-1004.
6. Wright PW, Wallace RJ, Wright NW, Brown BA, Griffith DE Sensitivity of fluorochrome microscopy for detection of Mycobacterium tuberculosis versus nontuberculous mycobacteria. J Clin Microbiol 1998, 36:1046-1049.
7. Diacon AH, Dawson R, Von Groote-Bidlingmaier F, et al. Randomized dose-ranging study of the 14-day early bactericidal activity of bedaquiline (TMC207) in patients with sputum microscopy smear-positive pulmonary tuberculosis. Antimicrob Agents Chemother 2013, 57:2199-2203.
8. Kayigire XA, Friedrich SO, Venter A, et al. Direct comparison of Xpert MTB/RIF assay with liquid and solid mycobacterial culture for quantification of early bactericidal activity. J Clin Microbiol 2013, 51:1894-1898.
9. Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012, 366:2151-2160.
10. Mitchison DA Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months. Am Rev Respir Dis 1993, 147:1062-1063.
11. Pheiffer C, Carroll NM, Beyers N, et al. Time to detection of Mycobacterium tuberculosis in BACTEC systems as a viable alternative to colony counting. Int J Tuberc Lung Dis 2008, 12:792-798.
12. Diacon AH, Maritz JS, Venter A, van Helden PD, Dawson R, Donald PR Time to liquid culture positivity can substitute for colony counting on agar plates in early bactericidal activity studies of antituberculosis agents. Clin Microbiol Infect 2012, 18:711-717.
13. Hesseling AC, Walzl G, Enarson DA, et al. Baseline sputum time to detection predicts month two culture conversion and relapse in non-HIV-infected patients. Int J Tuberc Lung Dis 2010, 14:560-570.
14. Wallis RS, Pai M, Menzies D, et al. Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. Lancet 2010, 375:1920-1937.
15. Walzl G, Ronacher K, Hanekom W, Scriba TJ, Zumla A Immunological biomarkers of tuberculosis. Nat Rev Immunol 2011, 11:343-354.
16. Kennedy N, Gillespie SH, Saruni AO, et al. Polymerase chain reaction for assessing treatment response in patients with pulmonary tuberculosis. J Infect Dis 1994, 170:713-716.
17. Desjardin LE, Perkins MD, Wolski K, et al. Measurement of sputum Mycobacterium tuberculosis messenger RNA as a surrogate for response to chemotherapy. Am J Respir Crit Care Med 1999, 160:203-210.
18. Honeyborne I, McHugh TD, Phillips PP, et al. Molecular bacterial load assay, a culture-free biomarker for rapid and accurate quantification of sputum Mycobacterium tuberculosis bacillary load during treatment. J Clin Microbiol 2011, 49:3905-3911.
19. van Zyl-Smit RN, Binder A, Meldau R, et al. Comparison of quantitative techniques including Xpert MTB/RIF to evaluate mycobacterial burden. PLoS One 2011, 6:e28815.
20. Helb D, Jones M, Story E, et al. Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. J Clin Microbiol 2010, 48:229-237.
21. Theron G, Peter J, van Zyl-Smit R, et al. Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting. Am J Respir Crit Care Med 2011, 184:132-140.
22. Blakemore R, Nabeta P, Davidow AL, et al. A multi-site assessment of the quantitative capabilities of the Xpert(R) MTB/RIF assay. Am J Respir Crit Care Med 2011, 184:1076-1084.
23. Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010, 363:1005-1015.
24. Rachow A, Zumla A, Heinrich N, et al. Rapid and accurate detection of Mycobacterium tuberculosis in sputum samples by Cepheid Xpert MTB/RIF assay-a clinical validation study. PLoS One 2011, 6:e20458.
25. Weyer K, Mirzayev F, Migliori G, et al. Rapid molecular TB diagnosis: evidence, policy-making and global implementation of Xpert(R)MTB/RIF. Eur Respir J 2012, published online Nov 22. 10.1183/09031936.00157212.
26. Pantoja A, Fitzpatrick C, Vassall A, Weyer K, Floyd K Xpert MTB/RIF for diagnosis of TB and drug-resistant TB: a cost and affordability analysis. Eur Respir J 2012, published online Dec 20. 10.1183/09031936.00147912.
27. Kent PT, Kubica GP Public health mycobacteriology: a guide for the level III laboratory 1985, US Department of Public Health and Human Services, Atlanta, GA.
28. Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med 2000, 4:1376-1395. American Thoracic Society.
29. Rustomjee R, Lienhardt C, Kanyok T, et al. A phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2008, 12:128-138.
30. Blakemore R, Story E, Helb D, et al. Evaluation of the analytical performance of the Xpert MTB/RIF assay. J Clin Microbiol 2010, 48:2495-2501.
31. Garton NJ, Waddell SJ, Sherratt AL, et al. Cytological and transcript analyses reveal fat and lazy persister-like bacilli in tuberculous sputum. PLoS Med 2008, 5:e75.
32. Li L, Mahan CS, Palaci M, et al. Sputum Mycobacterium tuberculosis mRNA as a marker of bacteriologic clearance in response to antituberculosis therapy. J Clin Microbiol 2010, 48:46-51.
33. Hellyer TJ, Fletcher TW, Bates JH, et al. Strand displacement amplification and the polymerase chain reaction for monitoring response to treatment in patients with pulmonary tuberculosis. J Infect Dis 1996, 173:934-941.
34. Miotto P, Bigoni S, Migliori GB, Matteelli A, Cirillo DM Early tuberculosis treatment monitoring by Xpert(R) MTB/RIF. Eur Respir J 2012, 39:1269-1271.